No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 6 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Akanda Corp. (AKAN) stock was $1.90 as of Oct 6, 2026, 2:17 PM EDT, down 0.52% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -96.8% · 3-year avg -90.7%/yr
Akanda Corp., operating through its various subsidiary entities, focuses on the cultivation, production, and distribution of cannabis products. The company's operations span the United Kingdom, Lesotho, and other global regions, with a specific aim to provide cannabis-derived items for medical and wellness purposes.
Drug Manufacturers - Specialty & Generic · Toronto, ON
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$404394.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AKAN | $61,495 | $1.90 | -0.52% | -96.82% | N/A | N/A | N/A |
| 2PRFX | $71,110 | $0.88 | -0.15% | -87.06% | -74.50% | N/A | vs AKAN |
| 3ZCMD | $31,083 | $1.79 | -6.28% | -99.89% | -84.76% | N/A | vs AKAN |
| 4MNDR | $30,251 | $1.23 | -3.99% | -99.03% | N/A | N/A | vs AKAN |
| 5PBM | $97,282 | $5.12 | +0.69% | -73.54% | N/A | N/A | vs AKAN |
| 6SLXN | $108,729 | $0.26 | -2.44% | -99.31% | N/A | N/A | vs AKAN |
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.90
High
N/A
